Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Applied Nutrition trades ahead of guidance in H125

(Sharecast News) - Supplements business Applied Nutrition said on Thursday that its H125 financial performance was ahead of guidance issued at the time of its IPO. Applied Nutrition said it has made "good progress" in the first half of the financial year, delivering revenue of £47.6m, comfortably ahead of guidance of £46.0m, representing a strong underpinning for its full-year guidance of £100.0m.

The London-listed group also noted that it continues to achieve a "robust" adjusted underlying earnings margin and cash conversion, both in line with market expectations.

Applied Nutrition will announce its interim results on 8 April.

Chief executive Thomas Ryder said: "I am pleased to report we have made strong progress in the first half, delivering performance ahead of our IPO guidance. Our growing global customer base highlights our appeal to a wide range of consumers, from everyday health-conscious individuals to professional athletes who rely on trusted sports nutrition products to fuel their performance.

"We are running into the second half of the year with confidence and remain committed to delivering our vision of being the world's most trusted and innovative sports nutrition, health and wellness brand."

As of 0930, Applied Nutrition shares were up 0.54% at 149.40p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.